The ADH1B and DRD2 gene polymorphism may modify the protective effect of the ALDH2 gene against heroin dependence

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 43, Issue , 2013, Pages 134-139

  Wang, Tzu Yun ^a,b,d   Lee, Sheng Yu ^a,b   Chen, Shiou Lan ^a   Chang, Yun Hsuan ^a   Chen, Shih Heng ^a   Chu, Chun Hsien ^a   Huang, San Yuan ^c   Tzeng, Nian Sheng ^c   Wang, Chen Lin ^b   Yeh, Pin Hsi ^b   Lee, I Hui ^a,b   Yeh, Tzung Lieh ^a,b   Yang, Yen Kuang ^a,b   Lu, Ru Band ^a,b  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^c TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^d Tainan Hospital   (Taiwan)

Author keywords

Addiction; ADH1B; ALDH2; DRD2; Heroin dependence

Indexed keywords

ALCOHOL DEHYDROGENASE; ALCOHOL DEHYDROGENASE 1B; ALDEHYDE DEHYDROGENASE ISOENZYME 2; DOPAMINE 2 RECEPTOR; UNCLASSIFIED DRUG;

ADH1B GENE; ADULT; ALDH2 GENE; ARTICLE; CHINESE; CONTROLLED STUDY; DNA POLYMORPHISM; DRD2 GENE; FEMALE; GENE FREQUENCY; GENE FUNCTION; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAN CHINESE; HEROIN DEPENDENCE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADULT; ALCOHOL DEHYDROGENASE; ALDEHYDE DEHYDROGENASE; ALLELES; DATA INTERPRETATION, STATISTICAL; FEMALE; GENE FREQUENCY; GENOTYPE; HEROIN DEPENDENCE; HUMANS; LOGISTIC MODELS; MALE; POLYMORPHISM, GENETIC; RECEPTORS, DOPAMINE D2; RISK; TAIWAN;

EID: 84872576094     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2012.12.011     Document Type: Article

References (64)

1. Agarwal D.P., Goedde H.W. Pharmacogenetics of alcohol metabolism and alcoholism. Pharmacogenetics 1992, 2:48-62.
2. American Psychiatric Association Diagnostic and statistical manual of mental disorder-IV 1994, American Psychiatric Association, Washington. 4th ed.
3. Berman S.M., Noble E.P. Reduced visuospatial performance in children with the D2 dopamine receptor A1 allele. Behav Genet 1995, 25:45-58.
4. Bosron W.F., Li T.K. Genetic polymorphism of human liver alcohol and aldehyde dehydrogenases, and their relationship to alcohol metabolism and alcoholism. Hepatology 1986, 6:502-510.
5. Bosron W.F., Ehrig T., Li T.K. Genetic factors in alcohol metabolism and alcoholism. Semin Liver Dis 1993, 13:126-135.
6. Brooner R.K., King V.L., Kidorf M., Schmidt C.W., Bigelow G.E. Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Arch Gen Psychiatry 1997, 54:71-80.
7. Burke W.J., Li S.W., Williams E.A., Nonneman R., Zahm D.S. 3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson's disease pathogenesis. Brain Res 2003, 989:205-213.
8. Burke W.J., Li S.W., Chung H.D., Ruggiero D.A., Kristal B.S., Johnson E.M., et al. Neurotoxicity of MAO metabolites of catecholamine neurotransmitters: role in neurodegenerative diseases. Neurotoxicology 2004, 25:101-115.
9. Cesura A.M., Pletscher A. The new generation of monoamine oxidase inhibitors. Prog Drug Res 1992, 38:171-297.
10. Chang S.L., Kenigs V., Moldow R.L., Zadina J.E. Chronic treatment with morphine and ethanol, but not cocaine, attenuates IL-1 beta activation of FOS expression in the rat hypothalamic paraventricular nucleus. Adv Exp Med Biol 1995, 373:201-208.
11. Chao Y.C., Liou S.R., Chung Y.Y., Tang H.S., Hsu C.T., Li T.K., et al. Polymorphism of alcohol and aldehyde dehydrogenase genes and alcoholic cirrhosis in Chinese patients. Hepatology 1994, 19:360-366.
12. Chen C.C., Lu R.B., Chen Y.C., Wang M.F., Chang Y.C., Li T.K., et al. Interaction between the functional polymorphisms of the alcohol-metabolism genes in protection against alcoholism. Am J Hum Genet 1999, 65:795-807.
13. *2 variant gene allele. Alcohol Clin Exp Res 1999, 23:1853-1860.
14. Comings D.E., Blum K. Reward deficiency syndrome: genetic aspects of behavioral disorders. Prog Brain Res 2000, 126:325-341.
15. Consalvi V., Mardh G., Vallee B.L. Human alcohol dehydrogenases and serotonin metabolism. Biochem Biophys Res Commun 1986, 139:1009-1016.
16. Crabb D.W., Edenberg H.J., Bosron W.F., Li T.K. Genotypes for aldehyde dehydrogenase deficiency and alcohol sensitivity. The inactive ALDH2(2) allele is dominant. J Clin Invest 1989, 83:314-316.
17. Dandre F., Cassaigne A., Iron A. The frequency of the mitochondrial aldehyde dehydrogenase I2 (atypical) allele in Caucasian, Oriental and African black populations determined by the restriction profile of PCR-amplified DNA. Mol Cell Probes 1995, 9:189-193.
18. Diana M., Peana A.T., Sirca D., Lintas A., Melis M., Enrico P. Crucial role of acetaldehyde in alcohol activation of the mesolimbic dopamine system. Ann N Y Acad Sci 2008, 1139:307-317.
19. Endicott J., Spitzer R.L. A diagnostic interview: the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry 1978, 35:837-844.
20. *Power 3.1: tests for correlation and regression analyses. Behav Res Methods 2009, 41:1149-1160.
21. Grandy D.K., Zhang Y., Civelli O. PCR detection of the TaqA RFLP at the DRD2 locus. Hum Mol Genet 1993, 2:2197.
22. Hou Q.F., Li S.B. Potential association of DRD2 and DAT1 genetic variation with heroin dependence. Neurosci Lett 2009, 464:127-130.
23. Huang S.Y., Lin W.W., Ko H.C., Lee J.F., Wang T.J., Chou Y.H., et al. Possible interaction of alcohol dehydrogenase and aldehyde dehydrogenase genes with the dopamine D2 receptor gene in anxiety-depressive alcohol dependence. Alcohol Clin Exp Res 2004, 28:374-384.
24. Kapasi A.A., Gibbons N., Mattana J., Singhal P.C. Morphine stimulates mesangial cell TNF-alpha and nitrite production. Inflammation 2000, 24:463-476.
25. Kendler K.S., Karkowski L., Prescott C.A. Hallucinogen, opiate, sedative and stimulant use and abuse in a population-based sample of female twins. Acta Psychiatr Scand 1999, 99:368-376.
26. Keung W.M., Vallee B.L. Daidzin: a potent, selective inhibitor of human mitochondrial aldehyde dehydrogenase. Proc Natl Acad Sci U S A 1993, 90:1247-1251.
27. Keung W.M., Vallee B.L. Daidzin and its antidipsotropic analogs inhibit serotonin and dopamine metabolism in isolated mitochondria. Proc Natl Acad Sci U S A 1998, 95:2198-2203.
28. Kidorf M., Disney E.R., King V.L., Neufeld K., Beilenson P.L., Brooner R.K. Prevalence of psychiatric and substance use disorders in opioid abusers in a community syringe exchange program. Drug Alcohol Depend 2004, 74:115-122.
29. Lamensdorf I., Eisenhofer G., Harvey-White J., Nechustan A., Kirk K., Kopin I.J. 3,4-Dihydroxyphenylacetaldehyde potentiates the toxic effects of metabolic stress in PC12 cells. Brain Res 2000, 868:191-201.
30. Lawford B.R., Young R.M., Noble E.P., Sargent J., Rowell J., Shadforth S., et al. The D(2) dopamine receptor A(1) allele and opioid dependence: association with heroin use and response to methadone treatment. Am J Med Genet 2000, 96:592-598.
31. Lee H.S. Gender-specific molecular heterosis and association studies: dopamine D2 receptor gene and smoking. Am J Med Genet B Neuropsychiatr Genet 2003, 118B:55-59.
32. Lee S.Y., Hahn C.Y., Lee J.F., Chen S.L., Chen S.H., Yeh T.L., et al. MAOA-uVNTR polymorphism may modify the protective effect of ALDH2 gene against alcohol dependence in antisocial personality disorder. Alcohol Clin Exp Res 2009, 33:985-990.
33. Li S.W., Lin T.S., Minteer S., Burke W.J. 3,4-Dihydroxyphenylacetaldehyde and hydrogen peroxide generate a hydroxyl radical: possible role in Parkinson's disease pathogenesis. Brain Res Mol Brain Res 2001, 93:1-7.
34. Li T., Liu X., Zhao J., Hu X., Ball D.M., Loh el W., et al. Allelic association analysis of the dopamine D2, D3, 5-HT2A, and GABA(A)gamma2 receptors and serotonin transporter genes with heroin abuse in Chinese subjects. Am J Med Genet 2002, 114:329-335.
35. Liu B., Gao H.M., Wang J.Y., Jeohn G.H., Cooper C.L., Hong J.S. Role of nitric oxide in inflammation-mediated neurodegeneration. Ann N Y Acad Sci 2002, 962:318-331.
36. *1 and DRD2/ANKK1 TaqI A1A1 genes may be associated with antisocial personality disorder not co-morbid with alcoholism. Addict Biol 2010, 17(5):864-874.
37. Maldonado R., Saiardi A., Valverde O., Samad T.A., Roques B.P., Borrelli E. Absence of opiate rewarding effects in mice lacking dopamine D2 receptors. Nature 1997, 388:586-589.
38. Mardh G., Vallee B.L. Human class I alcohol dehydrogenases catalyze the interconversion of alcohols and aldehydes in the metabolism of dopamine. Biochemistry 1986, 25:7279-7282.
39. Mattammal M.B., Haring J.H., Chung H.D., Raghu G., Strong R. An endogenous dopaminergic neurotoxin: implication for Parkinson's disease. Neurodegeneration 1995, 4:271-281.
40. Melis M., Enrico P., Peana A.T., Diana M. Acetaldehyde mediates alcohol activation of the mesolimbic dopamine system. Eur J Neurosci 2007, 26:2824-2833.
41. Merikangas K.R., Stolar M., Stevens D.E., Goulet J., Preisig M.A., Fenton B., et al. Familial transmission of substance use disorders. Arch Gen Psychiatry 1998, 55:973-979.
42. Noble E.P. D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes. Am J Med Genet B Neuropsychiatr Genet 2003, 116B:103-125.
43. Oosterhuis B.E., LaForge K.S., Proudnikov D., Ho A., Nielsen D.A., Gianotti R., et al. Catechol-O-methyltransferase (COMT) gene variants: possible association of the Val158Met variant with opiate addiction in Hispanic women. Am J Med Genet B Neuropsychiatr Genet 2008, 147B:793-798.
44. Osier M., Pakstis A.J., Kidd J.R., Lee J.F., Yin S.J., Ko H.C., et al. Linkage disequilibrium at the ADH2 and ADH3 loci and risk of alcoholism. Am J Hum Genet 1999, 64:1147-1157.
45. Pacifici R., di Carlo S., Bacosi A., Pichini S., Zuccaro P. Pharmacokinetics and cytokine production in heroin and morphine-treated mice. Int J Immunopharmacol 2000, 22:603-614.
46. Peng G.S., Wang M.F., Chen C.Y., Luu S.U., Chou H.C., Li T.K., et al. Involvement of acetaldehyde for full protection against alcoholism by homozygosity of the variant allele of mitochondrial aldehyde dehydrogenase gene in Asians. Pharmacogenetics 1999, 9:463-476.
47. Pohjalainen T., Rinne J.O., Nagren K., Lehikoinen P., Anttila K., Syvalahti E.K., et al. The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol Psychiatry 1998, 3:256-260.
48. Raghavendra V., Rutkowski M.D., DeLeo J.A. The role of spinal neuroimmune activation in morphine tolerance/hyperalgesia in neuropathic and sham-operated rats. J Neurosci 2002, 22:9980-9989.
49. Shahmoradgoli Najafabadi M., Ohadi M., Joghataie M.T., Valaie F., Riazalhosseini Y., Mostafavi H., et al. Association between the DRD2 A1 allele and opium addiction in the Iranian population. Am J Med Genet B Neuropsychiatr Genet 2005, 134B:39-41.
50. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998, 59(Suppl. 20):22-33. [quiz 4-57].
51. Smith M. Genetics of human alcohol and aldehyde dehydrogenases. Adv Hum Genet 1986, 15:249-290.
52. Svensson S., Some M., Lundsjo A., Helander A., Cronholm T., Hoog J.O. Activities of human alcohol dehydrogenases in the metabolic pathways of ethanol and serotonin. Eur J Biochem 1999, 262:324-329.
53. Thomasson H.R., Edenberg H.J., Crabb D.W., Mai X.L., Jerome R.E., Li T.K., et al. Alcohol and aldehyde dehydrogenase genotypes and alcoholism in Chinese men. Am J Hum Genet 1991, 48:677-681.
54. Tsuang M.T., Lyons M.J., Eisen S.A., Goldberg J., True W., Lin N., et al. Genetic influences on DSM-III-R drug abuse and dependence: a study of 3,372 twin pairs. Am J Med Genet 1996, 67:473-477.
55. Tsuang M.T., Lyons M.J., Meyer J.M., Doyle T., Eisen S.A., Goldberg J., et al. Co-occurrence of abuse of different drugs in men: the role of drug-specific and shared vulnerabilities. Arch Gen Psychiatry 1998, 55:967-972.
56. Volkow N.D., Wang G.J., Maynard L., Fowler J.S., Jayne B., Telang F., et al. Effects of alcohol detoxification on dopamine D2 receptors in alcoholics: a preliminary study. Psychiatry Res 2002, 116:163-172.
57. Wang T.Y., Lee S.Y., Chen S.L., Chen S.H., Chu C.H., Huang S.Y., et al. The aldehyde dehydrogenase 2 gene is associated with heroin dependence. Drug Alcohol Depend 2012, 120:220-224.
58. Westerink B.H., de Vries J.B. On the origin of dopamine and its metabolite in predominantly noradrenergic innervated brain areas. Brain Res 1985, 330:164-166.
59. Wurst F.M., Tabakoff B., Alling C., Aradottir S., Wiesbeck G.A., Muller-Spahn F., et al. World Health Organization/International Society for Biomedical Research on Alcoholism study on state and trait markers of alcohol use and dependence: back to the future. Alcohol Clin Exp Res 2005, 29:1268-1275.
60. Xu K., Liu X.H., Nagarajan S., Gu X.Y., Goldman D. Relationship of the delta-opioid receptor gene to heroin abuse in a large Chinese case/control sample. Am J Med Genet 2002, 110:45-50.
61. Xu K., Lichtermann D., Lipsky R.H., Franke P., Liu X., Hu Y., et al. Association of specific haplotypes of D2 dopamine receptor gene with vulnerability to heroin dependence in 2 distinct populations. Arch Gen Psychiatry 2004, 61:597-606.
62. Yoshida A., Hsu L.C., Yasunami M. Genetics of human alcohol-metabolizing enzymes. Prog Nucleic Acid Res Mol Biol 1991, 40:255-287.
63. Young R.M., Lawford B.R., Nutting A., Noble E.P. Advances in molecular genetics and the prevention and treatment of substance misuse: Implications of association studies of the A1 allele of the D2 dopamine receptor gene. Addict Behav 2004, 29:1275-1294.
64. Yuferov V., Levran O., Proudnikov D., Nielsen D.A., Kreek M.J. Search for genetic markers and functional variants involved in the development of opiate and cocaine addiction and treatment. Ann N Y Acad Sci 2010, 1187:184-207.